Show simple item record

dc.contributor.authorJames, ND
dc.contributor.authorIngleby, FC
dc.contributor.authorClarke, Noel W
dc.contributor.authorAmos, C
dc.contributor.authorAttard, G
dc.contributor.authorCross, W
dc.contributor.authorDearnaley, D
dc.contributor.authorGilbert, D
dc.contributor.authorJones, R
dc.contributor.authorLangley, R
dc.contributor.authorMason, MD
dc.contributor.authorMatheson, D
dc.contributor.authorParker, C
dc.contributor.authorRitchie, A
dc.contributor.authorRush, HL
dc.contributor.authorRussell, M
dc.contributor.authorMestre, RP
dc.contributor.authorParmar, MKB
dc.contributor.authorSydes, MR
dc.date.accessioned2019-12-09T17:23:32Z
dc.date.available2019-12-09T17:23:32Z
dc.date.issued2019en
dc.identifier.citationJames ND, Ingleby FC, Clarke NW, Amos C, Attard G, Cross W, et al. 855PD Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial. Annals of Oncology. 2019;30(Supplement_5).en
dc.identifier.doi10.1093/annonc/mdz248.008aen
dc.identifier.urihttp://hdl.handle.net/10541/622603
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz248.008aen
dc.titleDocetaxel for hormone-naive prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentClinical Trials Unit, Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birminghamen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-22T19:59:27Z


Files in this item

Thumbnail
Name:
mdz248.008a(1).pdf
Size:
79.85Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record